Nebenwirkungen · Bimervax
BIMERVAX XFG.1.1 emulsion for injection BIMERVAX XFG.1.1 emulsion for injection in pre-filled syringe COVID-19 Vaccine (recombinant, adjuvanted) · Abschnitt 4.8 · PDF-Seite 48
HOS-151302 · Präparat HOS-100493
The overall safety profile for the BIMERVAX XBB.1.16 booster dose was similar to that seen after the BIMERVAX (original, heterodimer B.1.351 and B.1.1.7 strains) booster dose. The most common adverse reactions reported were injection site pain (68.11%), headache (23.42%), fatigue (19.60%) and myalgia (13.62%). Most adverse reactions were mild to moderate in severity. No new adverse reactions were identified for the BIMERVAX XBB.1.16 booster dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T13:15:05Z · SHA-256 9021815ee653b04aa62b8ee1b9ae8cc9cdf72bb8edc2998f5a88fe9d974331b9 · Passage 8b7b88815b16ea1df7e9f41157d924f74e45d9a59c70fa822fe260122d7ade5e · Zeichen 1611–2061 im Abschnitt